- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05256472
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
September 17, 2023 updated by: Akeso
Phase II Trial of Cadonilimab (AK104) Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma (RCC)
This is a Phase II, open-label trial to evaluate the efficacy and safety of AK104 monotherapy or AK104 in combination with axitinib as a first-line treatment for advanced/metastatic renal cell carcinoma (RCC).
There are two parts in this trial.
In part 1 of this study, subjects with unresectable advanced clear cell or non-clear cell renal cell carcinoma (ccRCC or nccRCC) who had not received systemic therapy for advanced disease will be enrolled to randomly received three different dosage of AK104 monotherapy.
In part 2 of this study, subjects with unresectable advanced clear cell renal cell carcinoma (ccRCC) who had not received systemic therapy for advanced disease will be enrolled to receive AK104 plus Axitinib.
All subjects will receive treatment until disease progression, development of unacceptable toxicity, death, a decision by the physician or patient to withdraw from the trial.
The primary endpoint is ORR per RECIST v1.1 as assessed by investigators.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weifeng Song, MD
- Phone Number: +86(0760)89873999
- Email: clinicaltrials@akesobio.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Dingwei Ye, MD
- Phone Number: +86-13701663571
- Email: FUSCC2012@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provide written informed consent/assent for the trial.
- Be≥18 and ≤ 75 years of age on day of signing informed consent, no matter male or female.
- Have Karnofsky performance status (KPS) ≥ 70% as assessed within 10 days prior to first dosing of AK104.
- Have estimated life expectancy of at least 3 months.
- Have histologically or cytologically confirmed diagnosis of RCC with advanced/metastatic disease (i.e., Stage IV RCC per American Joint Committee on Cancer) with clear cell or non-clear cell component (part 1) or solely clear cell component (part 2).
- Have received no prior systemic therapy for advanced RCC . Note: Prior neoadjuvant/adjuvant therapies are acceptable if disease progression occurred > 12 months after last dosage of neoadjuvant/adjuvant treatment.
- Have measurable disease per RECIST 1.1 as assessed by the investigator /site radiologist. (brain metastases were excluded).
- Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.
Adequate organ function as determined by:
- Hematology: i. absolute neutrophil count (ANC) ≥ 1.5 × 109/L (1,500/mm3); ii. platelets ≥ 100 × 109/L (100,000/mm3); iii. hemoglobin ≥ 90 g/L.
- Renal: i. calculated creatinine clearance * (CrCl) ≥ 50 mL/min; * CrCl will be calculated using the Cockcroft-Gault formula CrCL (mL/min) = {(140-age) × body weight (kg) × F }/(SCr (mg/dL) × 72) Where F = 1 for males and F = 0.85 for females; SCr = serum creatinine. ii. urine protein < 2 + or 24-hour urine protein must be < 2.0 g.
- Hepatic: i. serum total bilirubin (TBil) ≤ 1.5 × ULN; ii. AST and ALT ≤ 2.5 × ULN, ≤ 3.0 × ULN with liver metastasis; iii. serum albumin (ALB) ≥ 28 g/L.
- Coagulation function: i. international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
- Cardiac Function: i. Left ventricular ejection fraction (LVEF) ≥ 50%.
Exclusion Criteria:
- Has a known additional malignancy that has progressed or has required active treatment in the last 3 years. Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or carcinoma in situ are not excluded.
- Has had prior treatment with any anti-PD-1, or PD-L1, or PD-L2 agent or an antibody targeting any other immune-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against IDO, IL-2R, GITR,CTLA-4,CD40, CD137.
- Has received prior therapy with VEGF/VEGFR or mTOR targeting agents.
- Has received radiotherapy within 14 days prior to start of study treatment and has not recovered adequately from any toxicity and/or complications from prior radiotherapy.
- Has newly diagnosed brain metastases or known symptomatic brain metastases requiring steroids. Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to receiving first dose of trial treatment, have discontinued corticosteroid treatment for these metastases for at least 3 days and are neurologically stable.
- Had major surgery 4 weeks or major radiation therapy 2 weeks prior to receiving first dose of trial treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed at least 48 hours prior to receiving first dose of trial treatment.
- Has active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Subjects with diabetes type I, vitiligo, psoriasis, hypo-or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to receiving first dose of trial treatment.
- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- Has an active tuberculosis and syphilitic infection.
- Has a known history of Human Immunodeficiency Virus (HIV) infection (HIV antibodies).
- Has known active Hepatitis B (e.g., Hepatitis B surface antigen [HBsAg] reactive and HBV-DNA>200 IU/ml) or Hepatitis C virus (e.g., HCV RNA [qualitative] is detected).
- Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥ 140 mm Hg and/or diastolic blood pressure (DBP) ≥ 90 mmHg.
- Has active bleeding disorder or other history of significant bleeding episodes within 30 days of screening.
- Has been pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment (30 days for axitinib, whichever occurs last).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AK104 monotherapy cohort (Part 1)
Subjects in this cohort will randomly receive three different dosage of AK104 monotherapy administered intravenously.
|
anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
|
Experimental: combination treatment cohort (Part 2)
Subjects in this cohort will receive AK104 (RP2D, administered intravenously) plus Axitinib 5 mg bid, administered orally.
|
anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR per RECIST v1.1 as assessed by investigators
Time Frame: Up to 2 years
|
ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: Up to 2 years
|
Overall survival is defined as the time from the start of treatment until death due to any cause.
|
Up to 2 years
|
Deep response rate
Time Frame: Up to 2 years
|
(% patients with >75% tumor reduction at 6 months ) per RECIST v1.1
|
Up to 2 years
|
Duration of response (DOR)
Time Frame: Up to 2 years
|
Duration of response (DOR) assessed according to RECIST v1.1
|
Up to 2 years
|
Disease control rate (DCR)
Time Frame: Up to 2 years
|
Disease control rate (DCR) assessed according to RECIST v1.1
|
Up to 2 years
|
Progression-free survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time from the the start of treatment till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the investigator or death due to any cause (whichever occurs first).
|
Up to 2 years
|
Peak Plasma Concentration (Cmax)
Time Frame: Up to 2 years
|
The maximum (or peak) plasma concentration of AK104 in subjects treated with AK104 plus axitinib.
|
Up to 2 years
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: Up to 2 years
|
AUC = Area under the plasma concentration of AK104-time curve.
The area under the plasma concentration time curve (AUC) is a measure of overall exposure to the drug
|
Up to 2 years
|
Immunogenicity assessment
Time Frame: Up to 2 years
|
Number and percentage of subjects with detectable anti-drug antibodies (ADAs) treated with AK104 plus axitinib
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dingwei Ye, MD, Shanghai Cancer Center of Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 6, 2023
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
January 24, 2022
First Submitted That Met QC Criteria
February 16, 2022
First Posted (Actual)
February 25, 2022
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 17, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Axitinib
Other Study ID Numbers
- AK104-213
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada
-
National Cancer Institute (NCI)TerminatedSorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell CarcinomaUnited States
Clinical Trials on AK104
-
AkesoNot yet recruiting
-
Second Affiliated Hospital of Zunyi Medical UniversityGuizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaboratorsRecruitingImmunotherapy | Second-line TreatmentChina
-
Wuhan Union Hospital, ChinaRecruiting
-
AkesoNot yet recruitingHepatocellular CarcinomaChina
-
AkesoActive, not recruitingAdvanced or Metastatic Solid TumorsAustralia
-
Chinese PLA General HospitalNot yet recruitingNon-small Cell Lung Cancer
-
Shengjing HospitalNot yet recruitingTriple Negative Breast CancerChina
-
Shanxi Province Cancer HospitalCancer Institute and Hospital, Chinese Academy of Medical SciencesRecruiting